BridgeBio Oncology Therapeutics Reports Q3 Net Loss of $34.2M, Cash Runway Into 2029

BridgeBio Oncology Therapeutics reported a third-quarter 2026 net loss of $34.2 million, compared with $44.8 million a year earlier. The company ended September with $315.3 million in cash, cash equivalents and marketable securities, which it expects to fund operations into 2029. Clinical updates i…